Skip to main content
Terug
Watch Compare

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Datakwaliteit: 100%
CELZ
Nasdaq Manufacturing Chemicals
€ 2,06
▼ € 0,16 (-7,01%)
Marktkapitalisatie: 7,60 M
Prijs
€ 2,06
Marktkapitalisatie
7,60 M
Dagbereik
€ 2,04 — € 2,25
52-Weeksbereik
€ 1,50 — € 6,25
Volume
52.706
Openen € 2,24
50D / 200D Gem.
€ 1,93
6,66% above
50D / 200D Gem.
€ 2,67
23,01% below

Quick Summary

Belangrijkste Punten

Revenue declined -48,86% annually over 5 years
Negative free cash flow of -5,86 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,41%

Groei

Revenue Growth (5Y)
-48,86%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-45,45%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-96,54%
Onder sectorgemiddelde (-53,41%)
ROIC-78,15%
Net Margin-99916,80%
Op. Margin-102380,23%

Veiligheid

Debt / Equity
N/A
Current Ratio20,71
Interest CoverageN/A

Waardering

PE (TTM)
-1,27
Boven sectorgemiddelde (-1,48)
P/B Ratio1,36
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,3 -1,5
P/B 1,4 1,6
ROE % -96,5 -53,4
Net Margin % -99916,8 -41,5
Rev Growth 5Y % -48,9 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -45,45% Revenue Growth (3Y) -18,35%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -48,86% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6.000,0 Net Income (TTM) -6,00 M
ROE -96,54% ROA -92,53%
Gross Margin 63,43% Operating Margin -102380,23%
Net Margin -99916,80% Free Cash Flow (TTM) -5,86 M
ROIC -78,15% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 20,71
Interest Coverage N/A Asset Turnover 0,00
Working Capital 5,15 M Tangible Book Value 5,15 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,27 Forward P/E N/A
P/B Ratio 1,36 P/S Ratio 1266,36
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -77,08%
Market Cap 7,60 M Enterprise Value 7,60 M
Per Share
EPS (Diluted TTM) -2,52 Revenue / Share 0,00
FCF / Share -1,58 OCF / Share -1,58
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 97,69%
SBC-Adj. FCF -5,87 M Growth Momentum 3,41

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.000,0 11.000,0 9.000,0 88.600,0 87.754,0
Net Income -6,00 M -5,49 M -5,29 M -10,14 M 19,21 M
EPS (Diluted) -2,52 -3,71 — -0,93 5,61
Gross Profit 3.806,0 6.600,0 5.400,0 60.109,0 39.805,0
Operating Income -6,14 M -5,74 M -5,62 M -10,24 M -3,13 M
EBITDA — — — — —
R&D Expenses 2,26 M 2,40 M 1,97 M 6,27 M 109.180,0
SG&A Expenses 3,76 M 3,24 M 3,56 M 3,94 M 2,96 M
D&A — 56.000,0 56.000,0 — —
Interest Expense — — — 0,0 4,28 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,81 M 6,67 M 10,72 M 19,19 M 11,27 M
Total Liabilities 284.880,0 327.644,0 371.394,0 3,32 M —
Shareholders' Equity 7,51 M 6,34 M 10,34 M 15,86 M 10,22 M
Total Debt — — — — —
Cash & Equivalents — — — — 10,72 M
Current Assets 7,40 M 6,14 M 10,27 M 18,75 M 10,74 M
Current Liabilities 284.880,0 327.644,0 371.394,0 3,32 M 1,05 M